Literature DB >> 30863568

How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.

Simon Garinet1,2, Audrey Didelot1, Elena Garelli3, Karine Pallier4, Hélène Blons1,2, Antoine Legras1,5.   

Abstract

Entities:  

Year:  2019        PMID： 30863568      PMCID： PMC6384333          DOI： 10.21037/jtd.2018.12.117

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  New lysine methyltransferase drug targets in cancer.

Authors:  Tobias Wagner; Manfred Jung
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

2.  The social aspects of EMT-MET plasticity.

Authors:  E W Thompson; I Haviv
Journal:  Nat Med       Date:  2011-09-07       Impact factor: 53.440

Review 3.  Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer.

Authors:  Nicole Vincent Jordan; Gary L Johnson; Amy N Abell
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

4.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis.

Authors:  Jeff H Tsai; Joana Liu Donaher; Danielle A Murphy; Sandra Chau; Jing Yang
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

5.  Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1.

Authors:  Oscar H Ocaña; Rebeca Córcoles; Angels Fabra; Gema Moreno-Bueno; Hervé Acloque; Sonia Vega; Alejandro Barrallo-Gimeno; Amparo Cano; M Angela Nieto
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

Review 6.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

7.  Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.

Authors:  Joseph A Sparano; Patricia Bernardo; Patricia Stephenson; William J Gradishar; James N Ingle; Stanley Zucker; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.

Authors:  Timothy F Burns; Irina Dobromilskaya; Sara C Murphy; Rajendra P Gajula; Saravanan Thiyagarajan; Sarah N H Chatley; Khaled Aziz; Yoon-Jae Cho; Phuoc T Tran; Charles M Rudin
Journal:  Mol Cancer Res       Date:  2013-01-30       Impact factor: 5.852

10.  Twisted epithelial-mesenchymal transition blocks senescence.

Authors:  Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2008-09       Impact factor: 28.824
View more
  1 in total

1.  The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.

Authors:  Guangyu Wang; Dandan Xu; Zicheng Zhang; Xinhui Li; Jiaqi Shi; Jie Sun; Huan-Zhong Liu; Xiaobo Li; Meng Zhou; Tongsen Zheng
Journal:  NPJ Precis Oncol       Date:  2021-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.